Enbrel vs XELJANZ

A medication that impacts your immune system is called ENBREL. Your immune system's capacity to combat infections may be diminished by ENBREL. Patients on ENBREL have experienced serious infections. These infections include those brought on by viruses, fungi, or bacteria that have spread throughout the body, as well as tuberculosis (TB). These infections have caused the deaths of several people.

 Even if you have tested negative for TB, your healthcare provider should test you for TB before you start taking ENBREL and closely monitor you for TB before, during, and after ENBREL treatment. ENBREL is recommended for patients with moderately to severely active rheumatoid arthritis in order to lessen signs and symptoms, prevent joint damage from getting worse, and improve physical function. ENBREL may be used alone or in combination with methotrexate.

ENBREL is recommended for psoriatic arthritis patients to lessen signs and symptoms, prevent further joint damage, and enhance physical function. It is possible to use ENBREL with or without methotrexate.

On the other hand, since its original approval in 2012, XELJANZ has been prescribed for individuals with moderate to severe rheumatoid arthritis for more than 9 years. Adults with moderate to severe ulcerative colitis received approval to use XELJANZ in 2017, while adults with active ankylosing spondylitis received approval in 2018.

A Janus kinase (JAK) inhibitor called XELJANZ works to block JAK pathways from within cells, which are thought to be involved in inflammation. Watch to find out more about the XELJANZ science and how JAK inhibitors are supposed to function.